Department of Dermatology, The Third Xiangya Hospital, Central South University, Changsha, China,
Xiangya School of Medicine, Central South University, Changsha, China,
Int Arch Allergy Immunol. 2021;182(10):917-931. doi: 10.1159/000515753. Epub 2021 Apr 29.
Urticaria is a type of skin disease characterized by rapid onset of hives (superficial dermis edema, erythema, pruritus, or burning sensation). According to whether the natural course exceeds 6 weeks, urticaria can be divided into acute and chronic urticaria (CU). At present, the evaluation of CU activity mainly depends on the Urticaria Activity Score (UAS), but the evaluation indicators are relatively single, and we need more reliable experimental data for evaluation. We typically summarize advanced biomarkers and several related pathogenic pathways discovered in recent years on urticaria, including the cell adhesion/chemotaxis pathway, interleukin (IL)-6/Janus tyrosine kinase/STAT pathway, IL-17/IL-23 pathway, basophil- and mast cell-related pathway, coagulation/fibrinolysis-related pathways, single-nucleotide polymorphism, and some other pathways. This review aims to find appropriate biomarkers so that we can evaluate disease activity, discover novel therapeutic targets, and predict the patients' response more accurately to therapeutic agents.
荨麻疹是一种以风团（真皮浅层水肿、红斑、瘙痒或烧灼感）迅速出现为特征的皮肤病。根据其自然病程是否超过 6 周，荨麻疹可分为急性和慢性荨麻疹（CU）。目前，CU 活动的评估主要依赖于荨麻疹活动评分（UAS），但评估指标相对单一，我们需要更可靠的实验数据进行评估。我们通常总结近年来在荨麻疹方面发现的先进生物标志物和几个相关的发病途径，包括细胞黏附/趋化途径、白细胞介素（IL）-6/Janus 酪氨酸激酶/STAT 途径、IL-17/IL-23 途径、嗜碱性粒细胞和肥大细胞相关途径、凝血/纤溶相关途径、单核苷酸多态性和其他一些途径。本综述旨在寻找合适的生物标志物，以便我们能够更准确地评估疾病活动、发现新的治疗靶点，并预测患者对治疗药物的反应。
